Afferent Pharmaceuticals, Inc.

Curasen Therapeutics, Inc.

Merck Sharp + Dohme Corp.

F. Hoffmann-La Roche Ag

Anthony P Ford

Prabha N Ibrahim

Ronald Charles Hawley

Joel R Gever

Jiaxin Yu

David Scott Carter

Steven A Smith

Bruce G McCarthy

Wei P Chen

Julian Paton

Torsten Hoffmann

Kathleen Sereda Glaub

Michael M Kitt

Gabriel Vargas

Wei Chen

Bruce G Mccarthy

Susanne Buser

Andrew John Sleight

Barbara Lenz

Steven Smith

Prabha Ibrahim

Pierre Vankan

The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor. In certain embodiments of the methods disclosed herein, the methods include administering to the subject a compound as disclosed herein and a peripherally acting P-blocker (PABRA).

Beta adrenergic agonist and methods of using the same

In various aspects and embodiments provided are compositions and methods for identifying patients in need of improving cognition and/or treating a neurodegenerative disease in a patient and treating such patient. More specifically, the disclosure in some embodiments includes administration of a &#x3b2;-AR agonist and a peripherally acting &#x3b2;-blocker (PABRA) to a patient in need thereof.

Methods for improving neurological diseases and disorders

In various aspects and embodiments provided are compositions and methods for a disease or disorder in a patient such as a disease or disorder that affects the brain in a patient and treating such patient.

Methods for treating neurological disorders with &#x3b1;-AR partial agonists

Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula I and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors: In one embodiment, the P2X3 and/or P2X2/3 antagonists disclosed herein are potentially useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.

Substituted pyrazole-pyrimidines, variants thereof, and uses therefore

Methods for treating cough, chronic cough and urges to cough associated with respiratory diseases with a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein Rand Rare as defined herein.

Diaminopyrimidine P2X3 and P2X2/3 receptor modulators for use in the treatment of cough

Provided are novel salts and polymorphs of 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide, which are potentially useful for modulating a condition mediated by a P2X3 or P2X2/3 receptor. Also provided are pharmaceutical formulations and methods of administration and dosing of these salts and polymorphs to subjects in need thereof.

Crystalline salts and polymorphs of a P2X3 antagonist

The present disclosure provides pyrimidine compounds of Formula 1 and uses thereof, for example, for the potential treatment of diseases associated with P2X purinergic receptors: In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the potential treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.

Pyrimidines and variants thereof, and uses therefor

The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.

Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula (I) and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors. In one embodiment, the P2X3 and/or P2X2/3 antagonists disclosed herein are potentially useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders. 

The present disclosure provides pyrimidine compounds and uses thereof, for example, for the treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.

The present disclosure provides pyrimidine compounds of Formula 1 and uses thereof for example, for the potential treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the potential treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders. 

Provided herein include methods and compositions for treating diseases or conditions. In some embodiments provided are methods for treating one or more diseases or conditions selected from the group consisting of hypertension, heart failure, dyspnea, and sleep apnea. In certain embodiments provided are methods that include administering a compound of formula (I) as disclosed herein. In some embodiments provided are methods that include administering a P2X3 and/or a P2X2/3 receptor antagonist.

Methods and compositions for treating diseases and conditions

Substituted pyrimidines for treatment of chronic cough, neuronal hypersensitivity underlying chronic cough, neuronal hypersensitivity underlying sub-acute cough and neuronal hypersensitivity underlying acute cough

Growing community of inventors

Palo Alto, CA, United States of America

Anthony P Ford